Other News To Note

• Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, said it submitted a marketing authorization application for Scenesse (afamelanotide 16-mg implant) to the European Medicines Agency (EMA) covering use of the product as a prophylactic treatment in adults with erythropoietic protoporphyria. Scenesse received orphan drug designation in 2008 and will be reviewed under the EMA's centralized procedure.